PMID- 26277887
OWN - NLM
STAT- MEDLINE
DCOM- 20160815
LR  - 20221207
IS  - 1463-1326 (Electronic)
IS  - 1462-8902 (Linking)
VI  - 17
IP  - 12
DP  - 2015 Dec
TI  - Efficacy and safety of pioglitazone added to alogliptin in Japanese patients with 
      type 2 diabetes mellitus: a multicentre, randomized, double-blind, 
      parallel-group, comparative study.
PG  - 1198-201
LID - 10.1111/dom.12555 [doi]
AB  - A phase IV, multicentre, randomized, double-blind, parallel-group, comparative 
      study was conducted in Japanese subjects with type 2 diabetes mellitus (T2DM) who 
      had inadequate glycaemic control, despite treatment with alogliptin in addition 
      to diet and/or exercise therapy. Subjects with glycated haemoglobin (HbA1c) 
      concentrations of 6.9-10.5% were randomized to receive 16 weeks' double-blind 
      treatment with pioglitazone 15 mg, 30 mg once daily or placebo added to 
      alogliptin 25 mg once daily. The primary endpoint was the change in HbA1c from 
      baseline at the end of treatment period (week 16). Both pioglitazone 15 and 30 mg 
      combination therapy resulted in a significantly greater reduction in HbA1c than 
      alogliptin monotherapy [-0.80 and -0.90% vs 0.00% (the least squares mean using 
      analysis of covariance model); p < 0.0001, respectively]. The overall incidence 
      rates of treatment-emergent adverse events were similar among the treatment 
      groups. Pioglitazone/alogliptin combination therapy was effective and generally 
      well tolerated in Japanese subjects with T2DM and is considered to be useful in 
      clinical settings.
CI  - (c) 2015 John Wiley & Sons Ltd.
FAU - Kaku, K
AU  - Kaku K
AD  - Department of Medicine, Kawasaki Medical School, Okayama, Japan.
FAU - Katou, M
AU  - Katou M
AD  - Takeda Development Center Japan, Takeda Pharmaceutical Company Limited, Osaka, 
      Japan.
FAU - Igeta, M
AU  - Igeta M
AD  - Takeda Development Center Japan, Takeda Pharmaceutical Company Limited, Osaka, 
      Japan.
FAU - Ohira, T
AU  - Ohira T
AD  - Takeda Development Center Japan, Takeda Pharmaceutical Company Limited, Osaka, 
      Japan.
FAU - Sano, H
AU  - Sano H
AD  - Takeda Development Center Japan, Takeda Pharmaceutical Company Limited, Osaka, 
      Japan.
LA  - eng
PT  - Clinical Trial, Phase IV
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20151023
PL  - England
TA  - Diabetes Obes Metab
JT  - Diabetes, obesity & metabolism
JID - 100883645
RN  - 0 (Dipeptidyl-Peptidase IV Inhibitors)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Piperidines)
RN  - 0 (Thiazolidinediones)
RN  - 0 (hemoglobin A1c protein, human)
RN  - 56HH86ZVCT (Uracil)
RN  - JHC049LO86 (alogliptin)
RN  - X4OV71U42S (Pioglitazone)
SB  - IM
MH  - Combined Modality Therapy/adverse effects
MH  - Diabetes Mellitus, Type 2/blood/diet therapy/*drug therapy/therapy
MH  - Diet, Diabetic
MH  - Dipeptidyl-Peptidase IV Inhibitors/adverse effects/*therapeutic use
MH  - Dose-Response Relationship, Drug
MH  - Double-Blind Method
MH  - Drug Resistance
MH  - Drug Therapy, Combination/adverse effects
MH  - Exercise
MH  - Glycated Hemoglobin/analysis
MH  - Humans
MH  - Hyperglycemia/*prevention & control
MH  - Hypoglycemic Agents/administration & dosage/adverse effects/*therapeutic use
MH  - Japan
MH  - Pioglitazone
MH  - Piperidines/adverse effects/*therapeutic use
MH  - Thiazolidinediones/administration & dosage/adverse effects/*therapeutic use
MH  - Uracil/adverse effects/*analogs & derivatives/therapeutic use
OTO - NOTNLM
OT  - alogliptin
OT  - combination therapy
OT  - glycaemic control
OT  - pioglitazone
OT  - type 2 diabetes mellitus
EDAT- 2015/08/19 06:00
MHDA- 2016/08/16 06:00
CRDT- 2015/08/18 06:00
PHST- 2015/05/20 00:00 [received]
PHST- 2015/06/07 00:00 [revised]
PHST- 2015/08/13 00:00 [accepted]
PHST- 2015/08/18 06:00 [entrez]
PHST- 2015/08/19 06:00 [pubmed]
PHST- 2016/08/16 06:00 [medline]
AID - 10.1111/dom.12555 [doi]
PST - ppublish
SO  - Diabetes Obes Metab. 2015 Dec;17(12):1198-201. doi: 10.1111/dom.12555. Epub 2015 
      Oct 23.